MedTrace Logo

Liquid Biopsy Based NGS in Newly Diagnosed NSCLC

NCT05853887 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2026-03-11

No results posted yet for this study

Summary

This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available prior to starting treatment so that physicians can make molecularly-informed treatment decisions. The second goal is to better understand factors that contribute to whether or not the EHR-nudge implementation is successful.

Conditions

  • Non Small Cell Lung Cancer Metastatic
  • Newly Diagnosed NSCLC
  • Non-Squamous Non-Small Cell Neoplasm of Lung

Interventions

BEHAVIORAL

iNUDGE

Electronic health record nudge which prompts physicians to order plasma-based NGS testing for eligible patients with newly diagnosed lung cancer.

Sponsors & Collaborators

Principal Investigators

  • Charu Aggarwal, MD, MPH · Penn Medicine

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-15
Primary Completion
2026-02-27
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05853887 on ClinicalTrials.gov